KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Change in Inventory (2023 - 2025)

Biocryst Pharmaceuticals' Change in Inventory history spans 5 years, with the latest figure at $515000.0 for Q4 2025.

  • For Q4 2025, Change in Inventory fell 76.19% year-over-year to $515000.0; the TTM value through Dec 2025 reached $1.6 million, down 60.64%, while the annual FY2025 figure was $1.6 million, 60.64% down from the prior year.
  • Change in Inventory reached $515000.0 in Q4 2025 per BCRX's latest filing, down from $1.7 million in the prior quarter.
  • In the past five years, Change in Inventory ranged from a high of $3.4 million in Q3 2023 to a low of -$1.4 million in Q2 2025.
  • Average Change in Inventory over 3 years is $604416.7, with a median of $692500.0 recorded in 2025.
  • Peak YoY movement for Change in Inventory: skyrocketed 1031.3% in 2024, then plummeted 94.59% in 2025.
  • A 3-year view of Change in Inventory shows it stood at -$907000.0 in 2023, then skyrocketed by 338.48% to $2.2 million in 2024, then plummeted by 76.19% to $515000.0 in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Change in Inventory are $515000.0 (Q4 2025), $1.7 million (Q3 2025), and -$1.4 million (Q2 2025).